https://www.stada.com/ 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/sitemap 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/about-stada 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/about-stada/who-we-are 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/about-stada/management 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee 2024-09-03T11:08:42+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/peter-goldschmidt 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/miguel-pagan 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/miguel-pagan-fernandez 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/boris-doebler 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/dr-christoph-dengler 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/christos-gallis 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/stéphane-jacqmin 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/frank-staud 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/volker-sydow 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/bryan-kim 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/boris-doebler-stadavoices 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/about-stada/management/stada-executive-committee/yann-brun 2024-09-03T11:09:04+00:00 yearly 0.5 https://www.stada.com/about-stada/management/supervisory-board 2025-06-05T16:47:13+00:00 monthly 0 https://www.stada.com/about-stada/our-corporate-culture 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/about-stada/stada-worldwide 2025-02-27T11:53:00+00:00 yearly 0.5 https://www.stada.com/about-stada/company-history 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/about-stada/compliance 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/products 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold 2024-09-03T11:08:42+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/aqualor 2024-09-03T14:09:59+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/bronchoforton 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/coldrex 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/cholinex 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/covonia 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/grippostad 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/lemocin 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/lisomucil 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/modafen 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/mebucaine 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/nasobol 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/orofar 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/pulmex 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/septofort 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/silomat 2024-09-20T09:00:52+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/sinulan 2024-09-06T14:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/cough-cold/snup 2025-06-03T13:46:38+00:00 monthly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/cetraben 2024-09-06T14:09:29+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/duofilm 2024-09-06T14:09:29+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/eurax 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/flexitol 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/hedrin 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/ladival 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/metanium 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/mitosyl 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/multilind 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/nizoral-terzolin 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/oilatum 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/psilo-balsam 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/savlon 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/derma/trofolastin 2024-09-06T14:10:05+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/biopron 2024-09-06T14:07:00+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/cetebe 2024-09-06T14:07:00+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/curazink 2024-09-06T14:07:00+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/degasin 2024-09-06T14:11:08+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/eat-all 2024-09-06T14:11:08+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/elotrans 2024-09-06T14:11:08+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/eunova 2024-09-06T14:11:08+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/frubiase 2024-09-06T14:18:43+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/magnetrans 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/martians 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/natures-aid 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/omnivit 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/spektrum 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/vitamins-minerals-gastro/walmark 2024-09-06T14:18:35+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/antistax 2024-09-06T14:11:42+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/hepathrombin 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/hirudoid 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/kamistad 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/mobilat 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/proenzi 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/radian 2024-09-06T13:30:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/synthol 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/pain-relief/venoruton 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/calm-sleep 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/calm-sleep/hoggar 2024-10-04T20:12:22+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/calm-sleep/lunestil 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/women-and-men-health 2024-09-13T11:19:34+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/women-and-men-health/prostenal 2024-09-06T14:12:08+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/women-and-men-health/urinal 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/other 2024-09-03T11:08:45+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/other/careplus 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/other/lomudal 2024-10-04T20:15:23+00:00 yearly 0.5 https://www.stada.com/products/consumer-healthcare-products/other/zoflora 2024-10-04T20:15:23+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/biosimilars 2024-09-03T11:08:42+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/bone-health 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/immunology 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/nephrology 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/neurology 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/oncology 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/products/specialty-pharmaceuticals/therapeutic-areas/ophthalmology 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/products/generics 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/products/partnerships 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/products/quality-at-stada 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/products/adverse-drug-reaction-report 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/stories/posts 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/stories/tags 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/stories/tags/diversity 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/tags/specialty 2024-09-03T11:08:42+00:00 yearly 0.5 https://www.stada.com/stories/tags/experts 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/stories/tags/brands 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/stories/tags/health-report 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/stories/tags/people 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/stories/tags/sustainability 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/stories/healthstories-take-your-time 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/making-a-difference-by-caring-for-peoples-health 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/empower-your-diversity-to-create-exponential-growth 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/histamine-intolerance-annoyance-instead-of-pleasure 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/understanding-parkinsons-disease 2025-04-08T08:57:24+00:00 monthly 0.5 https://www.stada.com/stories/after-diagnosis-everyday-life-with-parkinsons-tips-for-patients-and-relatives 2025-04-08T08:57:53+00:00 monthly 0.5 https://www.stada.com/stories/the-different-stations-of-parkinsons-therapy 2025-04-08T08:58:06+00:00 monthly 0.5 https://www.stada.com/stories/healthstories-get-yourself-moving 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/healthstories-be-kind-to-your-skin 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/nappy-rash 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/osteoporosis-prevention-care-the-right-choice-for-a-healthier-happier-you 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/health-stories-nourish-your-body-feed-the-soul 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/food-intolerances 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/urinary-tract-infection 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/sleep 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/healthy-lifestyle-and-supplements 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/common-cold-and-supplements 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/stories/preventive-healthcare 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/sleep-disorders-on-the-rise 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/dana-winkler-my-stada-story 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/jan-holt-growwithstada 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/timo-moeller-stada-countless-reasons 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/mental-health-matters 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/sdg-3-make-the-world-a-healthier-place 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/stada-s-people-are-the-key-of-our-growth 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/sdg-9-fostering-innovation-to-build-a-strong-world 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/catalina-medaru-countlessreasons 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/be-a-growth-mindsetter 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/reactivation-of-frubiase-sport-through-an-innovative-digital-campaign 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/sdg-12-excellence-should-always-be-stada-s-standard 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/healthreport-trust-in-conventional-medicine-on-the-rise 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/growth-mindsetters-around-the-world-international-mobility-at-stada 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/health-report-quotes 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/from-anti-dandruff-expert-to-no-1-scalp-health-brand-in-europe-how-stada-is-going-to-grow-the-brand-further 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/sdg-17-stada-manages-esg-practice 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/genetic-testing-can-help-detect-illnesses 2024-09-03T11:08:41+00:00 yearly 0.5 https://www.stada.com/stories/nearly-half-of-europeans-are-scared-of-ageing 2024-10-04T10:27:31+00:00 yearly 0.5 https://www.stada.com/stories/1-in-2-europeans-is-satisfied-with-their-looks 2024-10-28T07:13:07+00:00 yearly 0.5 https://www.stada.com/stories/fit-body-happy-mind-or-vice-versa 2025-01-10T16:08:29+00:00 yearly 0.5 https://www.stada.com/stories/the-loneliness-epidemic-how-are-europeans-coping 2025-01-10T16:08:36+00:00 yearly 0.5 https://www.stada.com/stories/topemployer 2025-01-16T08:17:49+00:00 yearly 0.5 https://www.stada.com/stories/from-vietnam-to-china-lunar-new-year-celebrations-at-stada 2025-02-06T07:08:50+00:00 yearly 0.5 https://www.stada.com/stories/stada-health-report-2024-recap 2025-02-10T07:20:34+00:00 yearly 0.5 https://www.stada.com/stories/women-in-science-voices-from-our-stada-experts 2025-02-17T10:48:28+00:00 yearly 0.5 https://www.stada.com/stories/rare-disease-day-2025-more-than-you-can-imagine 2025-02-26T07:24:00+00:00 yearly 0.5 https://www.stada.com/stories/world-kidney-day-2025-are-your-kidneys-ok 2025-03-13T07:00:47+00:00 monthly 0.5 https://www.stada.com/stories/celebrating-excellence-with-stadas-value-award-winners 2025-04-30T14:41:58+00:00 monthly 0.5 https://www.stada.com/stories/global-stadaplus-day 2025-07-10T14:52:19+00:00 monthly 0.5 https://www.stada.com/stories/celebrating-one-year-of-europe-s-first-ustekinumab-biosimilar-supplied-by-stada 2025-07-22T08:21:54+00:00 monthly 0.5 https://www.stada.com/stories/grow-your-own-way 2025-09-29T08:40:26+00:00 monthly 0.5 https://www.stada.com/stories/grow-your-own-way-from-dreaming-to-making-it-happen 2025-12-01T14:31:44+00:00 monthly 0.5 https://www.stada.com/stories/caringday 2025-12-10T16:21:56+00:00 monthly 0.5 https://www.stada.com/stories/stada-new-hero-glutosin 2026-01-08T13:18:25+00:00 monthly 0.5 https://www.stada.com/stories/from-dedication-to-recognition-we-are-a-top-employer-2026 2026-01-15T07:20:04+00:00 monthly 0.5 https://www.stada.com/stories/world-rare-disease-day-2026 2026-02-27T08:22:50+00:00 weekly 0.5 https://www.stada.com/sustainability 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report/esg-faqs 2025-05-08T10:32:49+00:00 monthly 0.5 https://www.stada.com/sustainability/sustainability-report/stories 2025-05-08T10:32:49+00:00 monthly 0.5 https://www.stada.com/sustainability/sustainability-report/stories/the-most-important-call-in-life-serbia 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report/stories/health-challenge-initiative-outgrowing-ourselves-together 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report/stories/construction-of-a-supply-chain-hub-in-romania 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report/stories/digitalization-of-leaflets-a-new-way-to-reduce-the-footprint 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/sustainability/sustainability-report/stories/governance-and-ethical-business-supported-by-green-it 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/sustainability/supply-chain-act 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/investor-relations 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/investor-relations/at-a-glance 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/investor-relations/financial-publications 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/investor-relations/financial-publications/financial-reports 2024-09-03T11:08:42+00:00 yearly 0.5 https://www.stada.com/investor-relations/corporate-governance 2025-08-31T16:08:34+00:00 monthly 0.5 https://www.stada.com/investor-relations/ir-contact 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/media 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/media/newsroom 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/media/press-releases 2026-01-16T08:10:44+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2026 2026-01-16T08:08:59+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2026/press-releases 2026-01-15T14:31:16+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2025 2026-01-15T14:28:20+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2025/press-releases 2025-01-08T18:49:58+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2024 2026-01-15T14:28:20+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2024/press-releases 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2023 2026-01-15T14:28:20+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2023/press-releases 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2022 2026-01-15T14:28:20+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2022/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2021 2026-01-15T14:28:20+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2021/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2020 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2020/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2019 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2019/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2019/information 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2019/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2018 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2018/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2018/ad-hoc-releases 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2018/interviews 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2018/information 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2018/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2017 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2017/press-releases 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2017/interviews 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2017/ad-hoc-releases 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2017/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2016 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2016/ad-hoc-releases 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2016/press-releases 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2016/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2015 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2015/interviews 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2015/ad-hoc-releases 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2015/press-releases 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2015/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2014 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2014/ad-hoc-releases 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2014/press-releases 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2014/interviews 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2014/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2013 2026-01-15T14:28:21+00:00 monthly 0.5 https://www.stada.com/media/press-releases/2013/ad-hoc-releases 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2013/press-releases 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/media/press-releases/2013/all 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/press-photos 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/media/press-photos/stada-executive-committee 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/media/press-photos/headquarters 2024-09-03T11:08:43+00:00 yearly 0.5 https://www.stada.com/media/press-photos/production 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/media/press-photos/development-quality-control 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/media/press-photos/historic-pharmacy 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/media/press-photos/historical-photos 2024-09-03T11:08:44+00:00 yearly 0.5 https://www.stada.com/media/health-reports 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report 2025-06-25T15:53:35+00:00 monthly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2025 2025-06-25T15:53:35+00:00 monthly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023 2025-06-25T15:53:35+00:00 monthly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/prevention 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/mental-health-and-sleep 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/war-and-crisis 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/cough-and-cold 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/pain-management 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/methodology 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2023/chronic-diseases 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/media/health-reports/stada-health-report-2021 2025-06-25T15:43:27+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2020 2025-06-25T15:43:27+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2019 2025-06-25T15:43:27+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2017 2025-06-25T15:43:27+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2016 2025-06-25T15:43:28+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2015 2025-06-25T15:43:28+00:00 monthly 0.5 https://www.stada.com/media/health-reports/health-report-2014 2025-06-25T15:43:28+00:00 monthly 0.5 https://www.stada.com/media/social-media 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/media/media-contact 2024-09-03T11:08:40+00:00 yearly 0.5 https://www.stada.com/career 2024-12-11T11:58:54+00:00 yearly 0.5 https://www.stada.com/career/timeless-talent 2026-02-25T15:23:08+00:00 weekly 0.5 https://www.stada.com/stada-health-report-2021 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/stada-health-report-2022 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/blog 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/blog/posts 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/blog/posts/2026 2026-01-16T08:09:08+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/january 2026-01-15T14:22:56+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/january/stada-s-head-of-communications-frank-staud-additionally-leads-global-government-affairs 2026-01-16T08:09:12+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/february 2026-02-12T14:19:30+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/february/stada-and-bio-thera-receive-european-marketing-authorization-for-gotenfia-a-biosimilar-to-simponi 2026-02-13T09:02:10+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/february/stada-invests-more-than-85m-in-saudi-arabia-manufacturing-hub 2026-02-16T15:14:45+00:00 monthly 0.5 https://www.stada.com/blog/posts/2026/march 2026-03-17T16:55:38+00:00 weekly 0.5 https://www.stada.com/blog/posts/2026/march/stada-s-strong-growth-journey-continues-in-2025 2026-03-18T06:59:09+00:00 weekly 0.5 https://www.stada.com/blog/posts/2026/march/stada-strikes-deal-with-curateq-for-neutropenia-biosimilars-in-europe 2026-03-30T15:38:46+00:00 daily 0.5 https://www.stada.com/blog/posts/2026/march/capvest-completes-majority-acquisition-of-stada 2026-03-31T12:12:27+00:00 daily 0.5 https://www.stada.com/blog/posts/2026/april 2026-04-01T12:46:31+00:00 daily 0.5 https://www.stada.com/blog/posts/2026/april/enzymatica-and-stada-sign-partnership-agreement-for-germany-and-austria 2026-04-01T14:01:24+00:00 daily 0.5 https://www.stada.com/blog/posts/2025 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/january 2025-01-08T18:42:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/january/stada-sets-course-for-the-future-experienced-healthcare-manager-andreas-fibig-to-become-chairman-of-the-board 2025-01-10T10:42:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/january/stada-s-stephan-eder-sets-access-manufacturing-and-sustainability-at-the-heart-of-medicines-for-europe-presidency 2025-01-13T11:59:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/february 2025-01-08T18:42:41+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/march 2025-01-08T18:42:50+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/march/stada-s-growth-journey-continues-in-2024-significant-increase-in-sales-and-profits-growing-ahead-of-the-market 2025-03-07T06:30:03+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/april 2025-01-08T18:43:04+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/may 2025-01-08T18:43:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/june 2025-01-08T18:43:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/june/stada-s-continued-resilient-growth-leads-to-record-earnings-in-q1 2025-06-03T07:06:08+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/june/stada-health-report-2025 2025-06-26T09:54:25+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/july 2025-01-08T18:43:31+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/july/stada-brings-in-henshaw-from-biogen-to-head-specialty-as-kim-leads-western-europe 2025-07-07T09:50:48+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/august 2025-01-08T18:43:39+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/august/bio-thera-and-stada-extend-biosimilars-alliance-to-tocilizumab 2025-08-22T13:02:11+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/august/stada-sees-strong-sales-and-earnings-growth-in-h1 2025-08-28T07:30:01+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/september 2025-01-08T18:43:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/september/bain-capital-and-cinven-to-sell-majority-stake-in-stada-to-capvest 2025-09-01T07:35:50+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/september/capvest-to-acquire-majority-stake-in-stada-from-bain-capital-and-cinven 2025-09-01T07:51:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/september/stada-expands-specialty-biosimilars-portfolio-through-european-approval-for-afiveg-aflibercept 2025-09-16T12:45:28+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/september/stada-further-builds-its-bone-health-and-oncology-offering-with-positive-chmp-opinion-on-denosumab-biosimilars 2025-10-24T08:43:28+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/october 2025-01-08T18:44:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/october/stada-sponsors-pingpongparkinson-world-championship-in-italy 2025-10-24T08:38:04+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/november 2025-01-08T18:44:11+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/november/stada-has-appointed-tomas-mihal-as-the-new-head-of-germany-and-member-of-the-global-stada-executive-committee 2025-11-05T10:43:57+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/november/sustainalytics 2025-11-17T13:38:16+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/november/stada-obtains-approvals-to-bring-denosumab-biosimilars-in-bone-health-and-oncology-to-patients-in-europe 2025-11-24T11:07:39+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/december 2025-01-08T18:44:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2025/december/stada-welcomes-pedersen-as-general-counsel 2025-12-03T13:17:11+00:00 monthly 0.5 https://www.stada.com/blog/posts/2025/december/golimumab-biosimilar-gotenfia-from-stada-and-bio-thera-receives-positive-chmp-opinion 2025-12-12T11:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2024 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2024/january 2024-09-03T11:08:48+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/january/zuellig-pharma-becomes-stada-philippines-exclusive-distribution-partner 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/january/stada-and-alvotech-secure-approval-for-uzpruvo-europe-s-first-ustekinumab-biosimilar-to-stelara 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/march/stada-continues-with-double-digit-sales-and-profit-growth-in-2023 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/april 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/may/xbrane-and-stada-partner-with-valorum-biologics-to-commercialize-ranibizumab-biosimilar-candidate-in-the-us 2024-09-03T11:09:12+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/may/stada-reduces-carbon-emissions-and-increases-its-renewable-energy-supply-on-sustainability-journey 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/may/bio-thera-and-stada-reach-exclusive-agreement-for-bat2506-a-proposed-golimumab-biosimilar-in-the-eu-and-uk 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/june/alvotech-and-stada-add-to-strategic-alliance-through-denosumab-partnership 2024-09-03T11:09:12+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/june/stada-health-report-2024 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/july/stada-launches-ustekinumab-biosimilar-in-europe 2024-09-03T11:09:12+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/july/stada-receives-european-commission-approval-to-expand-label-and-patient-group-for-iga-nephropathy-orphan-medicine 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/august/stada-continues-strong-growth-journey-in-the-first-half-of-2024 2024-09-03T11:09:12+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/october/ema-accepts-marketing-authorization-applications-for-avt03-a-proposed-denosumab-biosimilar 2024-10-10T10:21:42+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/october/new-stada-facility-in-romania-for-sustainable-medicines-supply-in-europe 2024-10-31T08:00:08+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2024/december/stada-welcomes-ingo-schachel-as-head-of-investor-relations 2024-12-02T12:12:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2023/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/january/stada-appoints-boris-doebler-as-chief-financial-officer 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/january/adalvo-and-stada-extend-their-strategic-partnership 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/february/ema-confirms-acceptance-of-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/march/stada-sustains-strong-momentum-with-double-digit-sales-and-profit-growth-in-2022 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/april/stada-and-xbrane-launch-ranibizumab-to-support-patient-access-in-europe 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/june/stada-fda-approves-biologics-facility-to-supply-key-medicine-to-patients-in-us 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/june/stada-appoints-christos-gallis-as-head-of-eastern-europe 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/july/stada-further-grows-its-european-consumer-healthcare-portfolio-by-acquiring-several-additional-brands-from-sanofi 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/august/stadas-excellent-results-in-h1-2023-indicate-a-record-annual-profit-of-1-bn-driven-by-consumer-healthcare-and-specialty 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/august/people-with-parkinson-s-experience-variations-in-effects-of-oral-medicines-but-lack-advice-international-survey-reveals 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/september/stada-health-report-2023-a-lack-of-prevention-is-eroding-europeans-health 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/september/stada-and-calliditas-announce-the-filing-for-full-marketing-authorization-for-kinpeygo-in-the-eu 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/november/stada-and-alvotech-receive-positive-chmp-opinion-for-europe-s-first-ustekinumab-biosimilar-to-stelara 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/november/stada-strikes-partnership-with-cr-sanjiu-in-china-to-drive-growth-of-its-cough-and-cold-portfolio 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2023/december/stada-further-improves-sustainability-ranking-again-rates-among-top-6-of-pharma-players-globally 2024-09-03T11:09:13+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2022/january 2024-09-03T11:08:50+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/january/stada-sets-up-for-success-with-erin-federman-as-global-biosimilars-commercial-head 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/january/stada-expands-production-network-with-eur50m-project-in-romania 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/january/ignis-therapeutics-and-stada-partner-for-apomorphine-subcutaneous-injection-in-china 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/february 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/march 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/march/stada-s-2021-above-market-development-strengthens-base-for-further-growth-especially-in-consumer-healthcare-and-specialty 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/april 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/april/alvotech-and-stada-pave-way-to-launching-hukyndra-avt02-a-citrate-free-high-concentration-biosimilar-to-humira-by-resolving-european-patent-dispute-with-abbvie 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/april/stada-brings-in-berndt-to-further-develop-specialties-and-biosimilars-offerings 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/may 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/may/stada-set-to-expand-specialty-portfolio-with-positive-chmp-opinion-on-kinpeygo-orphan-medicine-for-igan-kidney-disease 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/june/stada-and-alvotech-expand-therapy-options 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/june/people-with-parkinson-s-are-missing-out-on-regular-specialist-advice-in-much-of-europe 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/july/stada-health-report-2022-europe-experiencing-worsening-health-conditions 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/july/stada-welcomes-eu-approval-of-kinpeygo-for-adults-with-primary-iga-nephropathy 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/august 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/august/stada-mourns-cfo-dr-wolfgang-ollig 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/august/strong-in-market-performance-leads-stada-to-double-digit-growth 2024-09-03T11:09:23+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/september/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/september/stada-sets-standard-in-specialty-by-launching-the-first-medicine-authorized-in-the-eu-for-treating-rare-kidney-disease 2024-09-03T11:09:23+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/november 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/november/stada-and-xbrane-secure-eu-approval-for-ximluci-ranibizumab-biosimilar-referencing-lucentis 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/november/stéphane-jacqmin-joins-stada-from-sanofi-and-becomes-head-of-emerging-markets 2025-08-31T10:59:53+00:00 monthly 0.5 https://www.stada.com/blog/posts/2022/november/stada-starts-work-on-eur50m-facility-to-strengthen-european-medicines-supply 2024-09-03T11:09:23+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/december/alvotech-and-stada-broaden-access-to-adalimumab-biosimilar-in-europe 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2022/december/stada-ranks-among-top-10-of-pharma-firms-on-sustainability 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2021/january 2024-09-03T11:08:50+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/february 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/february/stada-launches-novel-parkinson-s-therapy-in-germany-and-austria 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/handelsblatt-stada-enters-the-cannabis-market-more-acceptance-for-therapy-that-is-still-stigmatised 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/stada-attracts-bryan-kim-as-global-head-of-specialties 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/stada-launches-medical-cannabis-for-therapy-of-chronic-pain-patients 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/frankfurter-allgemeine-zeitung-stada-wants-to-set-the-gold-standard 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/stada-shows-resilience-with-double-digit-growth-in-2020 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/stada-strengthens-oncology-offering-by-launching-bevacizumab-biosimilar 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/march/stada-focuses-even-more-on-a-future-oriented-growth-culture-head-of-global-human-resources-simone-berger-moves-up-to-stadas-executive-board 2024-09-03T11:09:30+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/april 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/may 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/june/stada-health-report-2021-a-year-that-changed-europe-s-health-landscape 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/june/stada-further-grows-european-consumer-healthcare-portfolio-by-acquiring-16-well-established-brands-from-sanofi 2024-09-03T11:09:26+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/june/stada-and-partner-xbrane-advance-biosimilar-ranibizumab-candidate 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/july/enzymatica-and-stada-extend-agreement-on-viruprotect-to-vietnam 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/july/calliditas-therapeutics-and-stada-partner-to-register-and-commercialize-specialty-therapy-for-iga-nephropathy-in-europe 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/july/stada-and-sanofi-strike-consumer-healthcare-distribution-agreement-in-selected-countries-in-europe 2024-09-03T11:09:26+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/august/stada-continues-to-outpace-the-market-in-h1-and-strengthens-basis-for-further-growth 2024-09-03T11:09:18+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/november 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2021/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2020/january 2024-09-03T11:08:50+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/january/wolfgang-ollig-to-become-new-cfo-of-the-stada-group 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/january/stada-to-acquire-established-otc-and-food-supplement-portfolio-in-the-philippines 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/january/aidan-fry-joins-stada-s-corporate-communications-team 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/february 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/february/stada-becomes-a-major-consumer-healthcare-player-by-acquiring-15-well-established-gsk-brands 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march/dr-stephan-eder-is-appointed-as-executive-vice-president-of-stada-russiacis 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march/stada-takes-clear-lead-in-russian-consumer-healthcare-sector 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march/stada-closes-acquisition-of-walmark-creating-a-winning-portfolio-for-central-europe 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march/stada-delivers-double-digit-growth-in-2019-as-it-invests-to-lead-consumer-healthcare-and-generics-core-segments 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/march/coronavirus-covid-19 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/thanks-production 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/stada-caring-for-peoples-health-as-a-trusted-partner 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/stada-responds-to-urgent-need-by-making-more-medicines 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/thank-you-pharmacy 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/stada-supports-authorities-with-tailored-donations-and-services 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/hope-placed-in-doctors-and-healthcare-professionals 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/april/thank-you-doctors 2024-09-03T11:09:30+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/may 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/may/bausch-plus-lomb-licenses-exclusive-rights-from-stada-and-xbrane-to-a-biosimilar-candidate-for-lucentis-ranibizumab-in-the-united-states-and-canada 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/june/nidda-healthcare-gmbh-intends-to-conduct-a-squeeze-out-of-minority-shareholders-in-stada-arzneimittel-ag-under-stock-corporation-law 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/june/stada-health-report-2020-europe-demands-compulsory-vaccinations 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/july/new-name-proven-strengths-stada-gmbh-becomes-stada-consumer-health-deutschland-gmbh 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/july/stada-health-report-2020-one-in-five-europeans-expects-rapid-return-to-normal 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/july/stada-friday-fact-look-into-the-future-polypill-divides-europe 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/august/nidda-healthcare-gmbh-sets-cash-compensation-for-the-transfer-of-the-shares-of-the-minority-shareholders-of-stada-arzneimittel-ag-at-9851-eur 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/august/anders-fogstrup-becomes-new-general-manager-of-stadapharm 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/august/stada-continues-to-grow-strongly-during-challenging-times 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/september/romaniszyn-leads-stada-poland-s-growth-strategy 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/september/stada-health-report-on-world-contraception-day-2020 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/september/yann-brun-to-become-new-evp-head-of-global-development-portfolio-regulatory-and-business-developmentlicensing-of-the-stada-group 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october/stada-expands-specialty-footprint-through-acquisition-of-innovative-therapy-for-treating-advanced-parkinson-s-disease 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october/european-pharmaceutical-company-stada-enters-exclusive-medical-cannabis-partnership-with-medipharm-labs 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october/enyzmatica-and-stada-extend-agreement-on-viruprotect-to-russia-poland-ukraine-and-cis-countries 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october/stada-health-report-on-world-osteoporosis-day-2020 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/october/stada-health-report-2020-europeans-don-t-want-to-live-forever-majority-open-to-assisted-dying 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/november/stada-arzneimittel-ag-and-nidda-healthcare-gmbh-settle-lawsuit-and-valuation-proceedings-with-shareholders-timely-registration-of-squeeze-out-expected 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/november/nico-reinhold-new-global-head-of-digital-communications-at-stada 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/november/dangerous-gaps-in-knowledge-one-third-of-europeans-believe-that-antibiotics-fight-viruses 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/november/stada-figure-of-the-month-digital-doctors-europeans-open-to-apps-on-prescription 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2020/december/stada-figure-of-the-month-vaccination-status 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2019/january 2024-09-03T11:08:50+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/february 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/march 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/march/dpa-stada-to-hire-hundreds-of-employees-strong-increase-in-earnings 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/march/stada-with-strong-growth-momentum-in-2018 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/march/success-in-patent-dispute-regarding-blood-pressure-lowering-drug-stada-introduces-amlodipinevalsartan-generic 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/march/end-of-patent-dispute-exforge-generics-stada-celebrates-comeback 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/april 2024-09-03T11:08:56+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/may/stada-health-report-2019-half-of-europeans-are-ready-for-dr-robot-and-treatments-via-webcam 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/may/apotheke-adhoc-stada-launches-generic-bortezomib-in-14-european-countries 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/may/strategic-biosimilar-development-partnership-stada-and-xbrane-strengthen-collaboration 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/june/stada-to-acquire-branded-otc-portfolio-from-gsk-to-strengthen-skin-care-business-in-europe 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/june/salvatore-butti-to-become-general-manager-italy-at-stada-group-eg-spa-and-crinos-spa 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/june/stada-wins-fundamed-award-as-best-generic-company-of-the-year-in-spain 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/june/eelco-ockers-appointed-executive-vice-president-germany-at-stada 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/july/international-bikini-day-one-in-two-germans-are-jealous-of-other-peoples-beach-body 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/july/stada-health-report-2019-germans-don-t-feel-like-cooking 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/july/stada-vietnam-30th-anniversary-of-pymepharco-and-opening-of-the-new-hoang-van-thu-pharmaceutical-factory 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/july/stada-figure-of-the-month-44-percent-of-germans-want-to-abolish-prescription-requirements 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/august/common-disease-burnout-syndrome-one-in-two-germans-has-battled-burnout-symptoms 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/august/stada-delivers-strong-first-half-2019-results 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/august/stada-teriparatide-biosimilar-movymia-for-treatment-of-osteoporosis-launched-in-24-countries 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/september/european-day-for-organ-donation-and-transplantation-opt-out-solution-would-double-number-of-organ-donors-in-germany 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/october/stada-health-report-2019-germans-europe-s-check-up-champions-expect-their-doctor-to-lend-them-an-ear 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/november/stada-to-acquire-walmark-a-leading-consumer-healthcare-company-in-central-europe 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/november/stada-invests-660-million-usd-in-takeda-s-otc-portfolio-in-russiacis-to-become-a-major-player-in-these-branded-markets 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/november/stada-recognized-as-company-of-the-year-emea-for-the-second-year-in-a-row 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/november/alvotech-and-stada-agree-on-strategic-biosimilar-partnership 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2019/december/stada-to-become-a-major-pharma-player-in-ukraine-by-acquiring-biopharma-s-pharmaceutical-prescription-and-consumer-health-business 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2018/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/january/internationalization-of-otc-brands-stada-agrees-to-early-termination-of-license-agreement-with-sanofi-for-head-lice-lotion-hedrin 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/february/stada-general-meeting-approves-domination-and-profit-and-loss-transfer-agreement-with-nidda-healthcare-gmbh-1 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/february/stada-general-meeting-approves-domination-and-profit-and-loss-transfer-agreement-with-nidda-healthcare-gmbh 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/february/stada-set-for-continuity-peter-goldschmidt-to-succeed-claudio-albrecht-as-ceo-on-1-september-2018 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/february/stada-arzneimittel-ag-supervisory-board-of-stada-arzneimittel-ag-appoints-peter-goldschmidt-as-new-chairman-of-the-executive-board-as-of-september-1-2018-1 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/more-focused-and-aggressive 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/stada-ema-started-the-evaluation-of-resubmitted-marketing-authorisation-application-for-biosimilar-pegfilgrastim 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/stada-executive-board-and-supervisory-board-of-stada-arzneimittel-ag-resolve-on-a-proposal-for-the-appropriation-of-profits-and-propose-a-dividend-in-the-amount-of-011-per-share 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/stada-records-positive-business-development-in-2017 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/ceo-albrecht-to-modernize-stada-biosimilars-to-focus-on-oncology-cns-diabetes-and-ophthalmology 2024-09-03T11:09:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/stada-domination-and-profit-and-loss-transfer-agreement-between-stada-arzneimittel-ag-and-nidda-healthcare-gmbh-takes-effect-beginning-of-acceptance-period-for-severance-offer 2024-09-03T11:09:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/march/stada-executive-board-of-stada-arzneimittel-ag-decides-to-file-application-related-to-change-of-sub-segment-of-the-stock-exchange 2024-09-03T11:09:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/april/changes-in-the-management-team-of-stada 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/may/stada-with-solid-business-development-in-the-first-quarter-of-2018 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june/stada-annual-general-meeting-approves-agenda-items-with-a-large-majority 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june/stada-arzneimittel-ag-consent-solicitation-for-stada-euro-bond-20152022 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june/stada-recovers-top-selling-product-and-will-distribute-the-parkinsons-medication-in-germany-and-scandinavia-in-the-future 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june/strategic-expansion-of-otc-portfolio-continues-stada-acquires-emea-rights-to-global-anti-dandruff-brand-nizoral-from-janssen-pharmaceutica 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/june/not-for-distribution-to-any-us-person-or-in-or-into-or-to-any-person-located-in-the-united-states 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july/stada-arzneimittel-ag-announcement-of-the-results-of-the-tender-offer-regarding-the-stada-bond-20152022 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july/xbrane-and-stada-enter-into-a-co-development-agreement-for-xlucane 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july/stada-voting-results-of-the-bondholders-meeting-on-july-17-2018-concerning-the-stada-bond-20152022-appointment-of-one-square-advisory-services-gmbh-as-joint-representative-and-adjournment-of-the-further-agenda-items 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july/stada-repurchases-rights-for-ladival 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/july/stada-launches-anti-cancer-drug-pemetrexed 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/august/stada-becomes-majority-shareholder-of-bioceuticals-arzneimittel-ag 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/august/information-about-valsartan 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/august/stada-s-business-development-in-the-first-six-months-of-2018-as-expected 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/september/stada-ceo-peter-goldschmidt 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/september/voting-results-of-the-bondholders-meeting-concerning-the-stada-bond-20152022 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/september/stada-invites-the-holders-of-the-stada-bond-to-participate-in-the-bondholders-meeting-and-to-vote-in-favor-of-the-proposed-resolutions 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/october/stada-wins-ggb18-award 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/november/stada-s-300-000-000-175-senior-notes-due-2022-announcement-of-an-instruction-to-grant-in-rem-securities 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/november/stada-completion-of-the-compliance-investigation 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/december/stada-increases-its-stake-in-pymepharco-in-vietnam 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/december/stada-s-eur-300-000-000-175-senior-notes-due-2022 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2018/december/i-want-to-stay-with-stada-for-the-long-term-an-interview-with-peter-goldschmidt 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2017/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/january/changes-in-the-executive-board-of-stada-arzneimittel-ag 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february 2024-09-03T11:08:52+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-arzneimittel-ag-confirms-receipt-of-non-binding-expressions-of-interest-in-takeover-bid 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-arzneimittel-ag-starts-talks-with-potential-bidders 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-supervisory-board-establishes-ad-hoc-committee 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-arzneimittel-ag-confirms-receipt-of-another-non-binding-expression-of-interest-in-takeover-bid 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-arzneimittel-ag-informs-about-receipt-of-binding-conditional-take-over-offer 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/february/stada-conducts-structured-and-open-bidding-process-with-all-interested-parties 2024-09-03T11:09:30+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march 2024-09-03T11:08:54+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-earnings-2016-slightly-above-expectations-growth-to-continue-in-2017 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-statement-on-media-reports 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-raises-medium-term-growth-targets 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-leverages-positive-momentum-and-raises-targets-for-future-oriented-program-stada-plus 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-postpones-press-and-analyst-conference-on-full-year-figures-2016-to-march-29-2017 2024-09-03T11:09:31+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/march/stada-final-figures-for-2016-confirm-good-year-end-results-medium-term-growth-targets-for-2019-raised 2024-09-03T11:09:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/april/stada-supports-the-voluntary-public-tender-offer-by-bain-capital-and-cinven 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/april/to-the-shareholders-of-stada-arzneimittel-ag-stada-supports-voluntary-public-tender-offer-by-bain-capital-and-cinven 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/april/dr-ralph-grobecker-to-become-managing-director-of-stada-s-otc-segment 2024-09-03T11:09:26+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/april/stada-publication-of-the-offer-document-on-the-voluntary-public-tender-for-stada-arzneimittel-ag-by-bain-capital-and-cinven 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/may/stada-very-good-start-in-first-quarter-2017 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/may/interview-with-dr-matthias-wiedenfels-on-the-occasion-of-the-publication-of-the-figures-for-the-first-quarter-of-2017 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/may/stada-executive-board-and-supervisory-board-of-stada-arzneimittel-ag-recommend-acceptance-of-the-voluntary-public-takeover-offer-by-bain-capital-and-cinven 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/june/holger-pohlen-is-new-director-of-media-relations-at-stada-arzneimittel-ag 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/june/stada-bain-capital-and-cinven-lower-the-minimum-acceptance-threshold-for-the-takeover-offer-to-stada-s-shareholders-from-75-percent-to-675-percent-acceptance-period-extended-until-june-22-2017 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/june/stada-arzneimittel-ag-voluntary-public-takeover-offer-by-bain-capital-and-cinven-not-successful 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/june/stada-arzneimittel-ag-voluntary-public-takeover-offer-by-bain-capital-and-cinven-fails 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/stada-arzneimittel-ag-confirms-that-bain-capital-and-cinven-are-considering-to-apply-for-an-exemption-from-one-year-exclusion-period-for-the-submission-of-a-renewed-voluntary-public-takeover-offer 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/changes-in-the-executive-board-of-stada-arzneimittel-ag 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/stada-arzneimittel-ag-appoints-new-chief-executive-officer-and-chief-financial-officer-incumbents-step-down-from-their-positions 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/bain-capital-and-cinven-applied-for-an-exemption-from-one-year-exclusion-period-for-the-submission-of-a-renewed-voluntary-public-takeover-offer-with-stada-s-consent 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/stada-supports-renewed-improved-takeover-offer-announced-by-bain-capital-and-cinven 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/bain-capital-and-cinven-publish-offer-document-on-the-renewed-voluntary-public-takeover-offer-for-stada-arzneimittel-ag 2024-09-03T11:09:31+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/july/executive-board-and-supervisory-board-of-stada-recommend-acceptance-of-the-renewed-takeover-offer-by-bain-capital-and-cinven 2024-09-03T11:09:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/stada-shows-good-operational-development-in-first-six-months-of-2017 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/minimum-acceptance-threshold-for-stada-takeover-by-bain-capital-and-cinven-reached 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/stada-takeover-offer-by-bain-capital-and-cinven-successful 2024-09-03T11:09:31+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/entering-into-negotiations-of-a-domination-and-profit-and-loss-pooling-agreement-between-stada-arzneimittel-ag-and-nidda-healthcare-holding-ag-1 2024-09-03T11:09:32+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/following-the-successful-takeover-vote-for-stada-members-of-the-supervisory-board-to-step-down-from-their-posts 2024-09-03T11:09:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/changes-on-the-supervisory-board-of-stada-arzneimittel-ag-due-to-the-takeover-by-bain-capital-and-cinven 2024-09-03T11:09:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/following-the-successful-takeover-vote-for-stada-members-of-the-supervisory-board-to-step-down-from-their-posts-1 2024-09-03T11:09:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/august/stada-annual-general-meeting-approval-of-the-actions-of-the-executive-board-for-financial-year-2016-postponed-guidance-2017-confirmed 2024-09-03T11:09:33+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/september/supervisory-board-of-stada-arzneimittel-ag-elects-dr-guenter-von-au-as-new-chairman 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/september/dr-claudio-albrecht-appointed-ceo-and-mark-keatley-cfo-of-stada-arzneimittel-ag 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/october/frank-staud-assumes-overall-responsibility-for-the-stada-brand-and-communications 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/october/luc-slegers-to-hand-over-responsibility-for-stada-europe-after-26-years 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/november/stada-shows-good-business-development-in-the-third-quarter-of-2017-and-the-first-nine-months 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/november/stada-health-report-2017-young-adults-lack-health-education 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2017/december/stada-domination-and-profit-and-loss-transfer-agreement-pursuant-to-sections-291-et-seqq-aktg-concluded-between-stada-arzneimittel-ag-and-nidda-healthcare-gmbh 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2016/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/january/stada-appointment-of-dr-matthias-wiedenfels-extended 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/february/stada-development-as-expected-in-2015-under-difficult-framework-conditions-dividend-to-increase-preliminary-outlook-for-2016-published 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/march/stada-development-in-2015-as-expected-under-difficult-framework-conditions-dividend-to-increase-outlook-for-2016-confirmed 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/april/stada-successful-refinancing-through-the-securing-of-additional-promissory-note-loans-of-a-total-of-euro-350-million 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/may/stada-first-quarter-of-2016-better-than-expected-reported-key-earnings-figures-substantially-higher-than-previous-year-very-strong-development-of-the-german-generics-segment 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/may/stada-stada-allows-elaborated-motion-from-active-ownership-fund-as-supplement-to-the-annual-general-meeting-2016 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/may/stada-significant-renewal-of-supervisory-board-brought-forward-by-two-years-annual-general-meeting-2016-postponed-to-august-26-2016 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/may/stada-begins-process-for-significant-renewal-of-its-supervisory-board 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/june/change-in-chief-executive-officer-at-stada-arzneimittel-ag 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/june/change-in-leadership-at-stada 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/july/important-step-on-the-path-to-reconfiguring-the-stada-supervisory-board 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/july/stada-approves-growth-targets-for-2019 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/july/stada-announces-agenda-for-the-annual-general-meeting-2016 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/july/stada-statement-on-media-reports 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august/stada-excellent-business-development-in-the-first-six-months-of-2016 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august/hartmut-retzlaff-resigns-from-office 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august/stada-shareholder-meeting-resolves-to-remove-supervisory-board-chairman-dr-martin-abend-from-the-supervisory-board 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august/stada-supervisory-board-elects-carl-ferdinand-oetker-as-new-chairman-of-the-board 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/august/stada-annual-general-meeting-2016 2024-09-03T11:09:29+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/september/leslie-iltgen-is-the-new-vice-president-investor-relations 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/september/stada-sebastian-kraemer-bach-to-take-on-responsibility-for-expanded-corporate-communications 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/october/stada-lays-the-groundwork-for-sustainable-growth 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/november/stada-records-further-growth-in-the-first-nine-months-of-2016-adjusted-net-income-of-at-least-euro-180-million-now-expected-for-full-year-2016 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/november/stada-receives-positive-opinion-from-the-ema-for-teriparatide-biosimilar 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/november/stada-acquires-uk-branded-product-company-natures-aid 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2016/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2015/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/february/stada-russian-stada-subsidiary-strengthens-branded-product-portfolio-in-the-mens-health-area 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/february/stadapharm-launches-device-independent-rapid-test-for-the-detection-of-ebola-infections 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/february/lothar-guske-ebola-rapid-test-positively-influences-both-patient-and-quarantine-management 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/february/stada-sales-and-earnings-targets-for-2014-at-group-level-met-crisis-in-the-market-region-ciseastern-europe-requires-impairments-on-goodwill-as-well-as-on-further-intangible-assets 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/march/dhl-integrates-stada-s-german-logistics-arm-into-own-business 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/march/stada-sales-and-earnings-targets-for-2014-at-group-level-met-dividend-should-be-stable-outlook-for-2015-confirmed 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/march/stada-stada-and-indian-pharmaceutical-company-hetero-sign-letter-of-intent-for-the-founding-of-a-contractual-joint-venture 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/april/stada-successful-refinancing-at-favorable-conditions-through-the-placement-of-a-further-corporate-bond-in-the-total-amount-of-euro-300-million 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/may/stada-sales-and-earnings-key-figures-in-the-first-quarter-of-2015-not-as-significantly-burdened-by-cis-crisis-as-expected-positive-trend-in-central-europe-germany-as-well-as-asiapacific-mena 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/june/stada-executive-board-gives-a-positive-summary-of-financial-year-2014-at-the-annual-general-meeting-and-confirms-outlook-for-2015 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/june/stada-group-makes-further-investment-in-serbian-location 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/august/stada-figures-for-the-first-half-of-2015-benefit-from-substantially-improved-development-in-q22015-central-europe-as-well-as-asiapacific-mena-with-excellent-development-ciseastern-europe-stabilized-considerably 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/august/stada-and-richter-signed-a-license-and-distribution-agreement-for-biosimilar-pegfilgrastim 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/august/new-russian-consul-general-visits-stada-as-first-german-company 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/august/stada-expands-branded-product-portfolio-with-addition-of-food-intolerances-area 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/september/stada-executive-board-contract-of-chairman-of-the-executive-board-hartmut-retzlaff-extended-by-five-years 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/september/stada-clarification-of-the-medias-incorrect-presentation-of-the-remuneration-for-the-stada-chairman-of-the-executive-board 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/september/stada-press-conference-growth-through-internationalization 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/september/third-capital-markets-day-stada-commits-to-russian-market-in-saint-petersburg 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/november/stada-appointment-of-helmut-kraft-as-chief-financial-officer-extended 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/november/stada-nine-month-results-show-strong-development-in-the-third-quarter-outlook-for-2015-confirmed 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/december/one-in-two-germans-do-not-know-enough-about-their-health 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/december/stada-stada-signs-contract-to-purchase-argentinian-generics-producer-vannier 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/december/stada-stada-strengthens-aesthetics-area-through-cooperation-with-croma-pharma-and-at-the-same-time-secures-access-to-botulinumtoxin-a 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2015/december/stada-legal-action-against-stada-s-serbian-subsidiary-has-been-resolved 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2014/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/january/stada-executive-board-contract-of-chief-financial-officer-helmut-kraft-extended-by-four-years 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/january/stada-exceeds-two-billion-euro-mark-in-sales 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/february/stada-local-insolvency-administrator-files-lawsuit-against-a-subsidiary-of-stada-arzneimittel-ag 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/february/stada-successfully-concluded-purchase-of-the-russian-branded-product-portfolio-aqualor-for-the-self-medication-of-sinusitis-and-sore-throat 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/march/stada-preliminary-figures-show-successful-financial-year-2013-dividend-to-increase-by-32-percent-outlook-for-2014-confirmed 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/march/stada-successful-financial-year-2013-adjusted-ebitda-reaches-new-record-high-dividend-to-increase-by-32-percent-2014-outlook-adjusted 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/may/stada-with-positive-development-in-the-first-quarter-of-2014-group-sales-rise-by-7-percent-reported-ebitda-and-reported-net-income-slightly-over-previous-year-level-despite-cis-crisis 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/may/stada-subsidiary-supports-victims-of-balkan-flood 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/june/three-questions-for-chairman-of-the-executive-board-hartmut-retzlaff 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/june/stada-executive-board-shows-satisfaction-with-financial-year-2013-at-annual-general-meeting-and-adheres-to-outlook-for-2014 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/june/stada-strengthens-its-branded-product-portfolio-by-purchasing-the-flexitol-rights-for-uk-and-ireland-a-dermatological-range-in-the-area-of-hand-and-foot-care 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/august/interview-with-chief-financial-officer-helmut-kraft-on-the-occasion-of-the-half-year-results 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/august/stada-solid-result-in-difficult-market-environment-group-sales-increase-by-4-percent-adjusted-key-earnings-figures-substantially-higher-than-previous-year-reported-net-income-approximately-at-prior-year-level 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/september/stada-expands-branded-product-strategy 2024-09-03T11:09:16+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/october/stada-plans-to-hand-german-logistics-business-over-to-a-globally-active-and-well-known-logistics-company 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/october/stada-in-licenses-teriparatide-and-further-expands-biosimilar-portfolio 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/october/new-stada-initiative-investigates-daily-approach-to-health 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/november/stada-good-result-despite-challenging-framework-conditions-group-sales-rise-by-4-percent-significant-increase-of-adjusted-ebitda-by-12-percent-and-adjusted-net-income-by-36-percent-outlook-for-2014-confirmed 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/november/stada-and-mabxience-enter-into-negotiations-over-adalimumab-biosimilar 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2014/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2013/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/january/stada-scholarships-support-the-advancement-of-charité-top-performers 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/january/stada-wins-discount-agreement-tenders-with-germany-s-three-largest-public-health-insurers 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/january/stadas-subsidiary-eurogenerics-increases-profitability-with-new-distribution-agreement-in-belgium 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/february/aok-11-tender-round-stada-takes-top-active-ingredients 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/february/stada-preliminary-figures-2012-demonstrate-successful-financial-year-dividend-to-increase-by-more-than-35-percent 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/march/stada-successful-financial-year-2012-adjusted-ebitda-at-record-level-dividend-to-increase-by-over-35-percent-positive-outlook-to-2014 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/march/stada-to-establish-logistics-and-distribution-center-in-dubai 2024-09-03T11:09:21+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/april/with-stada-diagnostik-stada-is-entering-the-personalized-drug-therapy-business 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may/stada-dr-matthias-wiedenfels-to-become-chief-corporate-development-and-central-services-officer-stadas-executive-board-expanded-to-four-with-additional-specialist-expertise 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may/stada-good-start-in-the-first-quarter-of-2013-organic-growth-accelerated 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may/main-sponsor-stada-celebrates-with-the-rsv-lahn-dill-wheelchair-basketball-team-concludes-successful-season 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may/stada-equips-medicines-with-2d-bar-code 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/may/stada-successful-placement-of-a-corporate-bond-in-the-amount-of-euro-350-million 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/june/stada-executive-board-gives-a-positive-summary-of-2012-at-annual-general-meeting-and-adheres-to-the-positive-outlook-till-2014-supervisory-board-members-approved 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/june/viagra-active-ingredient-patent-expiration-stada-group-launches-low-cost-alternative-in-the-market-to-treat-erectile-dysfunction 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/june/stada-website-in-new-guise-quicker-access-to-the-right-information-with-a-new-design-and-smartphone-optimization 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august/stada-in-exclusive-negotiations-on-the-purchase-of-the-british-otc-manufacturer-thornton-ross 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august/stada-dr-axel-mueller-resigns-his-executive-board-mandate 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august/stada-with-dynamic-sales-growth-in-the-first-half-of-2013 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august/stada-purchases-british-otc-manufacturer-thornton-ross 2024-09-03T11:09:27+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/august/stada-expands-diagnostics-portfolio-new-user-friendly-self-tests-for-five-areas-of-indication 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/september/foregoing-the-use-of-external-consultants-brings-millions-in-savings-stada-establishes-it-shared-service-center-for-the-group 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/october/stada-optimizes-german-sales 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/october/stada-strengthens-business-activities-in-russia-with-the-signing-of-a-contract-for-the-purchase-of-the-branded-product-portfolio-aqualor-for-the-self-medication-of-sinusitis-and-sore-throat 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/october/stada-expands-biosimilar-range-and-in-licenses-filgrastim-product-from-apotex-inc 2024-09-03T11:09:25+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/october/stada-s-business-development-in-the-first-six-months-of-2018-as-expected 2024-09-03T11:09:28+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/november/stada-records-satisfactory-development-in-the-first-nine-months-of-2013-sales-growth-of-8-percent-adjusted-ebitda-margin-at-198-percent 2024-09-03T11:09:17+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/november/stada-donates-medications-for-the-philippines 2024-09-03T11:09:22+00:00 yearly 0.5 https://www.stada.com/blog/posts/2013/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2012/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/january/stada-withdrawal-from-purchase-of-the-gruenenthal-branded-product-portfolio-in-central-europe 2024-09-03T11:09:15+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/january/stada-and-gruenenthal-agreed-on-the-purchase-of-a-branded-product-portfolio-also-for-the-eu-markets-in-central-europe-at-a-lower-purchase-price 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/january/stada-purchase-of-a-branded-product-portfolio-for-the-eu-markets-in-central-europe-successfully-concluded 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/january/stada-purchase-of-a-generics-business-in-switzerland-successfully-concluded 2024-09-03T11:09:26+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/february/stada-sells-irish-production-facility-and-thus-continues-to-be-in-line-with-planning-for-the-implementation-of 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/march/stada-2011-preliminary-results-confirm-operationally-successful-year-low-net-income-due-to-high-burdening-one-time-special-effects-dividend-to-remain-unchanged-at-eur-037-per-ordinary-share-positive-outlook-until-2014 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/march/stada-with-a-new-internet-presence-and-its-own-youtube-channel 2024-09-03T11:09:19+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/march/stada-founds-a-subsidiary-in-australia-business-activities-expected-to-commence-in-the-third-quarter-of-2012 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/march/stada-operationally-successful-financial-year-2011-increase-in-all-adjusted-key-earnings-figures-reported-key-earnings-figures-decrease-due-to-the-high-burdening-one-time-special-effects-positive-outlook-until-2014 2024-09-03T11:09:26+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/april/patrick-meschenmoser-heads-media-relations-at-stada 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/may/stada-excellent-start-in-q12012-increase-in-all-adjusted-key-earnings-figures-reported-key-earnings-figures-burdened-by-planned-one-time-special-effects-positive-outlook-until-2014-confirmed 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/may/stada-sales-companies-achieve-very-good-results-in-the-8th-aok-tender-round-in-the-german-generics-market 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/may/stada-agm-2012-executive-board-expects-further-growth-in-group-sales-and-earnings-positive-outlook-until-2014-confirmed 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/june/stada-sales-companies-once-again-successful-in-tenders-for-discount-agreements-in-the-german-generics-market-very-good-results-in-the-second-barmer-gek-tender-round 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/august/stada-sale-of-two-russian-production-facilities-in-the-context-of-the-production-restructuring-according-to-stada-build-the-future-expected-within-q32012 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/august/stada-records-positive-business-development-in-the-first-half-of-2012-outlook-remains-positive-to-2014 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/august/stada-signs-contract-on-the-sale-of-two-russian-production-facilities-and-thus-completes-another-significant-step-in-the-context-of-stada-build-the-future 2024-09-03T11:09:24+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/september/stada-group-takes-a-leading-position-in-the-third-barmer-gek-discount-agreement-round 2024-09-03T11:09:14+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/september/stada-sale-of-two-russian-production-facilities-successfully-closed-personnel-reduction-goal-in-the-context-of-stada-build-the-future-reached-earlier-than-planned 2024-09-03T11:09:20+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2012/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2011/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2011/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2010/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2010/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2009/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2009/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2008/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2008/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2007/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2007/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006 2026-01-15T14:22:42+00:00 monthly 0.5 https://www.stada.com/blog/posts/2006/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2006/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2005/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/july 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2005/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2004/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2004/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2003/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2003/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2002/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2002/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2001/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/june 2024-09-03T11:08:58+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2001/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/2000/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/2000/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999 2026-01-15T14:22:43+00:00 monthly 0.5 https://www.stada.com/blog/posts/1999/january 2024-09-03T11:08:49+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/february 2024-09-03T11:08:51+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/march 2024-09-03T11:08:53+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/april 2024-09-03T11:08:55+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/may 2024-09-03T11:08:57+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/june 2024-09-03T11:08:59+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/july 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/august 2024-09-03T11:09:00+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/september 2024-09-03T11:09:01+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/october 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/november 2024-09-03T11:09:02+00:00 yearly 0.5 https://www.stada.com/blog/posts/1999/december 2024-09-03T11:09:03+00:00 yearly 0.5 https://www.stada.com/blog/tags 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/contact 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/contact/arrival 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/privacy-policy 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/conditions-of-use 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/terms-and-conditions 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/disclaimer 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/imprint 2024-09-03T11:08:38+00:00 yearly 0.5 https://www.stada.com/newsletter 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/newsletter-confirmation 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/login-page 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/error-page-1 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/newsletter-double-opt-in 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/newsletter-error 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/thank-you 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/error-page 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/search 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/stada-worldwide 2024-09-03T11:08:39+00:00 yearly 0.5 https://www.stada.com/test 2025-01-27T12:04:11+00:00 yearly 0.5 https://www.stada.com/ecco-berlin-conference-contact-form 2025-02-17T12:38:35+00:00 yearly 0.5 https://www.stada.com/era-vienna-contact-form 2025-05-20T16:04:45+00:00 monthly 0.5 https://www.stada.com/terms-of-use-privacy-policy-for-the-stada-alumni-network 2025-07-01T13:40:03+00:00 monthly 0.5 https://www.stada.com/nephro-update-contact-form 2025-09-05T07:42:40+00:00 monthly 0.5 https://www.stada.com/igan-congress-contact-form 2025-09-05T07:45:03+00:00 monthly 0.5